Researchers from Renbio Inc. and Louisiana State University investigated the delivery of plasmid DNA encoding new glucagon-like peptide-1(GLP-1)-based biologics with MYO (Make Your Own) technology as a new therapeutic strategy. This approach ensures the continuous production of GLP-1-based biologics for an extended period, overcoming the need for weekly dosing.
The classic origin story for a biotech startup is that of a scientist who nurtures his work out of a university and to commercial success. For Link Biologics Ltd. and its TSG6-based pipeline, the story is the other way around; it began with now-CEO Reuben Dawkins meeting University of Manchester scientists Tony Day and Caroline Milner while he was on the lookout for “great science that needs help to make it to patients.” The three are now co-founders of Link, which spun out of the University of Manchester in 2021 and has four programs in three indications, all based on TSG-6 biology.
Yuanyi Wise Tech (Ningbo) Ltd. has prepared and tested new tricyclic compounds acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12V mutant) interaction inhibitors potentially useful for the treatment of cancer.
Agomab Therapeutics NV has identified new TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors designed for use in the treatment of idiopathic pulmonary fibrosis.
Deepcure Inc. has synthesized new 3,4-dihydroquinoxalin-2(1H)-ones acting as bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors. As such, they are described as potentially useful for the treatment of autoimmune, cardiovascular disease, inflammatory disorders, multiple sclerosis, psoriasis, gout, obesity, and sepsis, among others.
Genosco Inc. has patented new molecular glue degraders comprising cereblon-binding agents acting as GSPT and/or Myc proto-oncogene protein (c-Myc) degradation inducers designed for use in the treatment of cancer.
Tumors with strong immunosuppressive microenvironments such as microsatellite-stable colorectal cancer (MSS-CRC) remain unresponsive to immune checkpoint blockade therapy, with <20% of gastrointestinal tumors responding to therapy.
Researchers from Flare Therapeutics Inc. presented the preclinical profile of FX-111, a selective active androgen receptor (ARON) degrader, in models of prostate cancer.
Gliomas are malignant tumors in the brain characterized by aggressive growth, poor prognosis and high mortality, and for which effective therapies are still lacking. Zinc finger protein 207 (ZNF207) is highly expressed in gliomas and represents a promising therapeutic target; researchers from the China Pharmaceutical University have developed and presented data for the ZNF207 inhibitor TMLZ-G46.
RSS
